Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - PDS Biotechnology Corp | brhc10014377_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - PDS Biotechnology Corp | brhc10014377_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - PDS Biotechnology Corp | brhc10014377_ex31-1.htm |
| 10-Q - 10-Q - PDS Biotechnology Corp | brhc10014377_10q.htm |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the “Company”), on Form 10-Q for the quarter ended
June 30, 2020 (the “Report”), I, Michael King, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
| (1) |
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
| (2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Dated: August 13, 2020
|
/s/ Michael King
|
|
|
Michael King
|
||
|
Interim Chief Financial Officer
(Interim Principal Financial Officer and
Principal Accounting Officer)
|